Financial Architects Inc raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,661 shares of the company’s stock after purchasing an additional 10,025 shares during the period. Johnson & Johnson accounts for 1.5% of Financial Architects Inc’s holdings, making the stock its 17th biggest position. Financial Architects Inc’s holdings in Johnson & Johnson were worth $8,422,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Lenox Wealth Advisors Inc. increased its position in Johnson & Johnson by 0.7% during the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares during the last quarter. Ullmann Financial Group Inc. acquired a new stake in Johnson & Johnson during the first quarter worth about $186,000. Taylor Wealth Management Partners increased its position in Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after purchasing an additional 250 shares during the last quarter. Finally, Foundation Resource Management Inc. acquired a new stake in Johnson & Johnson during the first quarter worth about $204,000. 65.90% of the stock is currently owned by institutional investors and hedge funds.
In related news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
WARNING: “Johnson & Johnson (JNJ) Holdings Boosted by Financial Architects Inc” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/19/johnson-johnson-jnj-holdings-boosted-by-financial-architects-inc.html.
JNJ has been the subject of several recent analyst reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price objective for the company in a research report on Monday, May 29th. BMO Capital Markets restated a “buy” rating and set a $132.00 price objective on shares of Johnson & Johnson in a research report on Friday, June 2nd. Cowen and Company restated an “outperform” rating and set a $143.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, June 13th. Royal Bank Of Canada restated a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 15th. Finally, Jefferies Group LLC restated a “hold” rating and set a $140.00 price objective on shares of Johnson & Johnson in a research report on Friday, June 16th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $134.50.
Johnson & Johnson (NYSE JNJ) traded down 0.1183% during mid-day trading on Tuesday, reaching $135.2199. 2,074,430 shares of the company traded hands. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The stock has a market capitalization of $362.93 billion, a PE ratio of 22.8798 and a beta of 0.79. The firm’s 50-day moving average is $132.72 and its 200 day moving average is $129.35.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period last year, the business posted $1.74 earnings per share. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.